🔍 Definition
Neuropathy refers to functional disturbance or pathological change in the peripheral nervous system — encompassing a broad spectrum of disorders affecting sensory, motor, and/or autonomic nerve fibers. The term encompasses mononeuropathy (single-nerve involvement), mononeuropathy multiplex (multiple non-contiguous nerves), and polyneuropathy (diffuse, often length-dependent involvement of multiple nerves). Peripheral nerves may be damaged by metabolic insults, immune-mediated mechanisms, toxic exposures, hereditary defects, compressive/entrapment forces, ischemia, infiltration, or infection.
From a coding perspective, neuropathy should be documented with the etiology, pattern, and fiber type when known. The FY2027 ICD-10-CM Official Guidelines require coders to apply the “with” convention under Section I.A.15: when diabetes mellitus and neuropathy are both documented, the linkage is presumed unless the provider clearly documents that the conditions are unrelated.
Clinically, neuropathy is divided into:
- Large-fiber neuropathy: Impairs proprioception, vibration sense, deep tendon reflexes; detected on nerve conduction velocity (NCV) studies.
- Small-fiber neuropathy (SFN): Affects pain and temperature fibers (Aδ and C fibers); NCV/EMG are typically normal in isolated SFN; diagnosis is supported by compatible clinical findings plus objective small-fiber testing such as skin punch biopsy for intraepidermal nerve fiber density (IENFD), quantitative sensory testing, or autonomic/sudomotor testing when clinically indicated.
- Autonomic neuropathy: Involves the autonomic nervous system; may cause orthostatic hypotension, gastroparesis, neurogenic bladder, sudomotor dysfunction.
Peripheral neuropathy is not a single ICD-10-CM code. Documentation must specify: (1) etiology (diabetic, alcoholic, drug-induced, hereditary, idiopathic, etc.), (2) distribution pattern (mononeuropathy vs. polyneuropathy), and (3) fiber type when available. Assign the most specific code available per FY2027 ICD-10-CM coding guidelines.
🗂️ Alternative Terminology
Clinicians, patients, and referring providers use many terms to describe neuropathy. Coders and CDI specialists must recognize lay and clinical synonyms to query appropriately and assign the correct code.
| Formal / ICD-10-CM Term | Colloquial / Lay / Clinical Synonyms |
|---|---|
| Polyneuropathy | Peripheral neuropathy, peripheral nerve damage, stocking-glove neuropathy, length-dependent neuropathy, distal symmetric polyneuropathy (DSPN) |
| Diabetic polyneuropathy (E11.42) | Diabetic nerve damage, diabetic feet numbness, diabetic peripheral neuropathy (DPN) |
| Mononeuropathy — carpal tunnel (G56.0) | Carpal tunnel syndrome (CTS), median nerve compression at wrist, repetitive strain neuropathy |
| Sciatic neuropathy (G57.0) | Sciatica, sciatic nerve pain, piriformis syndrome (when compressive) |
| Hereditary motor and sensory neuropathy (G60.0) | Charcot-Marie-Tooth disease (CMT), peroneal muscular atrophy, HMSN |
| Guillain-Barré syndrome (G61.0) | GBS, acute inflammatory demyelinating polyneuropathy (AIDP), ascending paralysis |
| Chronic inflammatory demyelinating polyneuropathy (G61.81) | CIDP, chronic relapsing polyneuropathy |
| Multifocal motor neuropathy (G61.82) | MMN, multifocal motor neuropathy with conduction block |
| Drug-induced polyneuropathy (G62.0) | Chemotherapy-induced peripheral neuropathy (CIPN), medication neuropathy, taxane neuropathy, platinum neuropathy |
| Alcoholic polyneuropathy (G62.1) | Alcohol-related neuropathy, ethanol neuropathy |
| Small fiber neuropathy | SFN, burning feet syndrome, erythromelalgia-type neuropathy (when vasomotor) |
| Autonomic neuropathy (G90.x / E11.43) | Dysautonomia, autonomic dysfunction, diabetic autonomic neuropathy (DAN) |
| Post-herpetic neuralgia (B02.29; B02.22 for trigeminal) | PHN, shingles nerve pain, post-zoster pain |
| Tarsal tunnel syndrome (G57.5) | Posterior tibial nerve entrapment, ankle tunnel syndrome |
| Meralgia paresthetica (G57.1) | Lateral femoral cutaneous nerve entrapment, burning thigh pain |
🩺 Signs & Symptoms
Symptoms vary substantially by fiber type and distribution. Thorough documentation of the symptom constellation guides code specificity and supports medical necessity for electrodiagnostic studies.
Sensory Symptoms
- Numbness, tingling, or “pins and needles” (paresthesia) — typically distal/stocking-glove in polyneuropathy
- Burning pain, allodynia, hyperalgesia — common in small-fiber predominant neuropathy and CIDP
- Loss of proprioception and vibration sense → sensory ataxia, positive Romberg sign
- Loss of pain/temperature sensation (small fiber) → risk of unnoticed wounds
Motor Symptoms
- Distal muscle weakness (foot drop in peroneal neuropathy, wrist drop in radial neuropathy)
- Atrophy of intrinsic hand muscles (ulnar/median neuropathy)
- Hyporeflexia or areflexia (ankle jerks lost early in length-dependent polyneuropathy)
- Fasciculations in severe axonal loss
Autonomic Symptoms
- Orthostatic hypotension, dizziness on standing
- Gastroparesis, constipation or diarrhea, nausea
- Neurogenic bladder (hesitancy, retention, incontinence)
- Anhidrosis or gustatory sweating
- Sexual dysfunction; fixed heart rate (cardiovascular autonomic neuropathy)
Entrapment / Mononeuropathy-Specific
- Carpal tunnel: nocturnal hand paresthesias, thenar atrophy, positive Tinel/Phalen signs
- Ulnar neuropathy: ring/little finger numbness, intrinsic weakness, claw hand
- Peroneal neuropathy: foot drop, steppage gait
- Sciatic neuropathy: posterior thigh/leg pain, weakness of knee flexion and all distal muscles
- Meralgia paresthetica: anterolateral thigh burning/numbness, no motor deficit
When documentation records “peripheral neuropathy” in a patient with Type 2 diabetes mellitus, ICD-10-CM Guideline I.A.15 presumes the diabetes/neuropathy relationship when both conditions are documented, unless the provider clearly documents that the neuropathy is unrelated to diabetes. Query when the record is clinically ambiguous, when another etiology is documented or suspected, or when specificity is needed for pattern (mono vs. poly) and fiber type (large, small, autonomic, mixed).
🧭 Differential Diagnosis
Accurate code assignment requires distinguishing neuropathy type and etiology. The following differentials are commonly encountered in inpatient, outpatient, and post-acute settings.
| Diagnosis | Key Distinguishing Features | ICD-10-CM Starting Point |
|---|---|---|
| Diabetic polyneuropathy (DSPN) | Symmetric, distal, stocking-glove; length-dependent; linked to glycemic control; NCV slowed | E11.42 (T2DM), E10.42 (T1DM) |
| CIDP | Progressive proximal + distal weakness; demyelinating NCS; responds to IVIG/steroids; relapsing | G61.81 |
| Guillain-Barré (GBS) | Acute ascending weakness; post-infectious (Campylobacter, viral); areflexia; CSF albuminocytologic dissociation | G61.0 |
| Charcot-Marie-Tooth (CMT) | Hereditary; onset childhood/adolescence; pes cavus, hammer toes; family history; gene mutation | G60.0 |
| Drug-induced (CIPN) | Taxanes, platinum, vinca alkaloids, thalidomide; temporal link to chemotherapy; sensory > motor | G62.0 + T-code adverse effect |
| Alcoholic neuropathy | Chronic heavy alcohol use; painful sensory neuropathy; nutritional deficiency co-exists | G62.1 |
| Vitamin B12 deficiency neuropathy | Posterior column involvement; subacute combined degeneration; macrocytic anemia possible; E53.8 + D51.x | E53.8, D51.x + G32.0 |
| Vasculitic neuropathy | Mononeuropathy multiplex pattern; painful; systemic vasculitis markers; nerve biopsy confirmation | G63 + underlying vasculitis M30-M31.x |
| Radiculopathy | Root-distribution pain/sensory loss; single dermatomal pattern; imaging-confirmed compression; not peripheral nerve | M54.1x, M50.1x, M51.1x |
| Carpal tunnel syndrome | Median nerve compression at wrist; nocturnal symptoms; Tinel/Phalen positive; NCS confirmatory | G56.00–G56.03 |
| Post-herpetic neuralgia | History of herpes zoster; dermatomal burning pain post-rash; allodynia | B02.29 (PHN; B02.22 for trigeminal distribution) |
| Small fiber neuropathy (SFN) | Burning pain, autonomic features; normal NCS/EMG; low IENFD on skin biopsy; normal large-fiber reflexes | G60.3 or G62.89 depending on etiology |
| Autonomic neuropathy | Orthostatic hypotension, gastroparesis, sudomotor dysfunction; cardiovascular autonomic neuropathy in diabetes | G90.x or E11.43 |
| Critical illness polyneuropathy | ICU setting; sepsis/SIRS; diffuse weakness, weaning failure; axonal on NCS | G62.81 |
📋 Clinical Indicators
The following indicators, when present in documentation, support specific neuropathy code assignment and justify diagnostic procedures, treatments, and higher resource utilization levels.
| Clinical Indicator | Coding / CDI Implication |
|---|---|
| Documented “diabetic neuropathy” or “neuropathy due to diabetes” | Use E11.4x–E10.4x combination codes; do NOT separately code G62.x; “with” convention applies (Guideline I.A.15) |
| Nerve conduction velocity (NCV) study with slowing | Supports demyelinating polyneuropathy; supports CPT 95907–95913; documents severity |
| EMG with denervation/reinnervation findings | Supports axonal neuropathy; supports CPT 95860–95872 or combined 95885–95887 |
| Skin punch biopsy with reduced IENFD | Supports small fiber neuropathy when interpreted with the clinical picture; CPT 11104 for a punch biopsy of skin, single lesion/site, and +11105 for each additional punch biopsy site; code G60.3, G62.89, or etiology-specific |
| Orthostatic blood pressure drop ≥20/10 mmHg | Supports autonomic neuropathy; query for autonomic neuropathy documentation (G90.3 or E11.43) |
| Prior chemotherapy agents (taxanes, platinum, vinca alkaloids) | Code G62.0 + adverse effect T-code (T45.1x5A ongoing treatment) |
| IVIG infusion ordered for neuropathy | Supports CIDP (G61.81) or MMN (G61.82); query for specific diagnosis; J1569 for Gammagard Liquid |
| Autonomic function testing (cardiovagal, adrenergic/tilt-table, sudomotor, or combined studies) | CPT 95921–95924 and 95943, as applicable; supports G90.x coding; document indication, test components, interpretation, and report in the clinical note |
| HbA1c > 7% + neuropathy symptoms | Clinical indicator to link neuropathy to diabetes; confirm physician documentation before coding |
| Pes cavus, hammertoes, family history of neuropathy | Suggests hereditary neuropathy (CMT G60.0); query genetic testing results, family history, gene mutation |
| Alcohol use disorder + distal sensory neuropathy | Code G62.1 alcoholic polyneuropathy; also code F10.2x for alcohol dependence |
| Vitamin B12 < 200 pg/mL + posterior column signs | Subacute combined degeneration G32.0; code also E53.8 and D51.x; may affect MS-DRG weight |
| Post-infectious ascending paralysis (GBS) | G61.0; query precipitating infection (Campylobacter A04.5, CMV B25.x, influenza); may require intubation/plasmapheresis |
Do not code “peripheral neuropathy” (G62.9) when a more specific etiology code is available. G62.9 (polyneuropathy, unspecified) is a last-resort code per ICD-10-CM Official Coding Guidelines. Diabetic neuropathy must use E08.4x–E13.4x combination codes (never G62.9 + E11). Drug-induced neuropathy requires G62.0 + an adverse effect T-code, not G62.9 alone.
🦴 Anatomy & Pathophysiology
The peripheral nervous system (PNS) consists of all neural structures outside the brain and spinal cord: cranial nerves (III–XII), spinal nerve roots, dorsal root ganglia, peripheral nerve trunks, plexuses, and the autonomic nervous system. Peripheral nerves are composed of:
- Large myelinated fibers (Aα, Aβ): Motor function, proprioception, vibration, and light touch.
- Small myelinated fibers (Aδ): Sharp pain, temperature, and some autonomic fibers.
- Unmyelinated fibers (C fibers): Burning pain, temperature, and postganglionic autonomic fibers (sudomotor, vasomotor, cardiac).
Major Pathophysiological Mechanisms
- Axonal degeneration: Direct axon injury (metabolic, toxic, ischemic); length-dependent (longest fibers affected first); Wallerian degeneration; slow/incomplete recovery. Seen in diabetic, toxic, and nutritional neuropathies.
- Segmental demyelination: Myelin sheath breakdown; conduction slowing on NCS; can be immune-mediated (CIDP, GBS) or hereditary (CMT type 1). Remyelination possible with treatment.
- Mixed axonal-demyelinating: Most common pattern in chronic polyneuropathies; seen in CIDP, severe diabetic neuropathy.
- Compression/entrapment: Mechanical focal demyelination then axon loss at anatomical tunnels (carpal tunnel, cubital tunnel, tarsal tunnel, fibular head).
- Immune-mediated: Antibody-mediated (anti-ganglioside antibodies in GBS/MMN, anti-CNTN1 in CIDP variants); complement activation; T-cell infiltration.
- Metabolic: Hyperglycemia → advanced glycation end-products (AGEs), polyol pathway activation, oxidative stress, mitochondrial dysfunction → nerve ischemia and axon loss in diabetic neuropathy per ADA Standards of Care.
- Vasculitic: Nerve ischemia from epineurial vessel inflammation → mononeuropathy multiplex pattern; requires nerve biopsy for definitive diagnosis.
Anatomical Entrapment Sites
- Median nerve: carpal tunnel (wrist), pronator syndrome (forearm), anterior interosseous syndrome
- Ulnar nerve: cubital tunnel (elbow), Guyon’s canal (wrist)
- Radial nerve: spiral groove (wrist drop), posterior interosseous nerve at radial tunnel
- Common peroneal (fibular) nerve: fibular head — most common lower limb entrapment
- Tibial nerve: tarsal tunnel (medial ankle)
- Lateral femoral cutaneous nerve: inguinal ligament → meralgia paresthetica
💊 Medication Impact / Treatment
Pharmacologic management of neuropathy varies substantially by etiology and must be reflected in documentation to support medical necessity and accurate HCC risk adjustment.
Pain / Symptom Management
- Gabapentinoids: Gabapentin (Neurontin), pregabalin (Lyrica) — one evidence-supported medication class for painful diabetic neuropathy; AAN guidance recommends offering TCAs, SNRIs, gabapentinoids, and/or sodium channel blockers while considering comorbidities, adverse effects, and cost; supports documentation of “painful neuropathy”
- SNRIs: Duloxetine (Cymbalta) — FDA-approved for diabetic peripheral neuropathic pain; documents severity and treatment
- TCAs: Amitriptyline, nortriptyline — second-line; document pain level and response
- Topical agents: Capsaicin 8% topical system (Qutenza) — used for focal peripheral neuropathic pain; report the product with HCPCS J7336 (capsaicin 8% patch, per square centimeter) and follow payer guidance for the professional administration service; do not use CPT 64616 for Qutenza application
- Opioids: Avoid routine use for painful diabetic neuropathy; if used in rare refractory circumstances, document the rationale, prior nonopioid treatment failures, risk/benefit discussion, and monitoring plan
- Lidocaine patches: Topical; limited evidence; document as adjunct
Disease-Modifying / Etiology-Specific
- IVIG (Intravenous Immunoglobulin): Standard of care for GBS (acute), CIDP (maintenance), MMN; AAN Practice Advisory; HCPCS J1569 (Gammagard Liquid 500 mg) per infusion visit
- Plasma exchange (plasmapheresis): GBS, CIDP; documents severity — typically inpatient; MS-DRG 023–024
- Corticosteroids: Prednisone or IV methylprednisolone for CIDP; document diagnosis and response
- Subcutaneous immunoglobulin (SCIG): Home maintenance for CIDP; J1561 (Gamunex) or J1569
- Rituximab: Refractory CIDP, anti-MAG neuropathy, vasculitic neuropathy; J9310
- Vitamin B12 (cyanocobalamin): B12-deficiency neuropathy; J3420 (IM injection); document deficiency etiology (D51.0 pernicious anemia vs E53.8)
- Thiamine (B1): Alcoholic neuropathy co-treatment; document alcohol use disorder + nutritional deficiency
- Glycemic optimization: Primary modifier for diabetic neuropathy; document HbA1c trend, insulin/oral agents, and complication stabilization or progression
Chemotherapy-Induced Neuropathy (CIPN)
Document the specific offending agent (taxane, platinum, vinca alkaloid, bortezomib, thalidomide) to code G62.0 with an appropriate adverse effect T-code. Dose modification or discontinuation of chemotherapy due to neuropathy must be documented by the oncologist and reflected in coding for episode-of-care reporting. Per ASCO guidelines, duloxetine is the only agent with moderate evidence for CIPN pain relief.
Preview ends here. The full guide continues with FY2027 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.
← Back to All Clinical Documentation Guides
📘 ICD-10-CM Guidelines
Section I.A.15 — “With” Convention (Diabetic Neuropathy)
Under FY2027 ICD-10-CM Official Guidelines Section I.A.15, the word “with” in a code title or instructional note establishes a presumed causal relationship between two conditions. When a patient with any type of diabetes mellitus has documented neuropathy and both conditions are listed in the medical record, coders must assign the diabetic neuropathy combination code (E08.4x–E13.4x) — even if the provider does not explicitly state “due to diabetes.” The provider need not use the exact phrase “due to diabetes”; documentation of both conditions in the same encounter is sufficient. Exception: If the provider explicitly states the neuropathy is NOT related to diabetes, that provider’s statement governs.
Do NOT code E11.40 (diabetic neuropathy, unspecified) when a more specific diabetic neuropathy code is documented: E11.41 (mononeuropathy), E11.42 (polyneuropathy), E11.43 (autonomic neuropathy), E11.44 (amyotrophy), or E11.49 (other). Auditors will flag E11.40 when chart documentation clearly supports a more specific subcategory. Similarly, do not code both E11.42 and G62.x — the diabetic combination code replaces separate peripheral neuropathy codes.
Code-Also and Etiology/Manifestation Convention
- Polyneuropathy in diseases classified elsewhere (G63): Always a manifestation code; requires an underlying condition code first (e.g., vasculitis M30-M31.x, amyloidosis E85.x, hypothyroidism E03.x, sarcoidosis D86.x, paraneoplastic — code neoplasm first).
- Post-herpetic neuropathy: Use B02.22 (postherpetic trigeminal neuralgia) or B02.29 (other postherpetic nervous system involvement including polyneuropathy). Do not use G53 for postherpetic trigeminal neuralgia (G53 Excludes1, FY 2027 Tabular); ICD-10-CM index directs “Post-herpetic neuralgia” → B02.29 for most sites.
- Drug-induced neuropathy (G62.0): “Code first” (T36–T65) adverse effect or poisoning code. For correctly prescribed medications causing neuropathy, use the adverse effect T-code with 5th character A (initial), D (subsequent), or S (sequela). Example: Paclitaxel neuropathy → G62.0 + T45.1x5A.
- Toxic neuropathy (G62.2): “Code first” (T51–T65) toxic substance. Example: Lead neuropathy → G62.2 + T56.0x1A.
- Radiation-induced neuropathy (G62.82): Code also Y84.2 (radiological procedure as cause) or use appropriate external cause code when applicable.
- Vitamin B12 deficiency neuropathy: Subacute combined degeneration of spinal cord G32.0 — code also E53.8 (B12 deficiency) and D51.x (if associated anemia). Sequence by documentation of principal diagnosis.
- Critical illness polyneuropathy (G62.81): Code also the critical illness (sepsis A41.x, systemic inflammatory response syndrome, ARDS J80) that caused the neuropathy.
Mononeuropathy Laterality
Most mononeuropathy codes under G56–G57 require laterality: 0 = unspecified side, 1 = right, 2 = left, and 3 = bilateral when a bilateral code exists in the tabular list. Coders must query for side documentation when the clinical record is unclear. Bilateral involvement should be reported with the bilateral code when one exists; otherwise, follow the tabular list and payer policy for reporting right- and left-sided codes.
Small Fiber Neuropathy (SFN) — No Dedicated Code
FY2027 ICD-10-CM does not contain a specific code for small fiber neuropathy. Assignment depends on etiology: idiopathic/cryptogenic SFN → G60.3 (idiopathic progressive neuropathy) or G62.89 (other specified polyneuropathy); SFN in diabetes → E11.4x; SFN in autoimmune disease → G63 + underlying condition. Document IENFD result (fibers/mm), skin biopsy site, and diagnosis statement to support specificity.
Autonomic Neuropathy Coding
Autonomic neuropathy codes fall under both Chapter 6 (G90.x) and the diabetes combination codes (E11.43, E08.43, etc.). When autonomic neuropathy is diabetic in etiology, use the E-code combination (E11.43 = Type 2 DM with diabetic autonomic neuropathy). Assign G90.x codes for non-diabetic autonomic disorders: G90.3 (multi-system atrophy with orthostatic hypotension — Shy-Drager), G90.1 (familial dysautonomia/Riley-Day), G90.09 (other idiopathic peripheral autonomic neuropathy).
🔢 ICD-10-CM Code Set (Tabular)
All codes verified against the FY2027 ICD-10-CM Tabular List and Index (CMS.gov) effective October 1, 2026.
G56 — Mononeuropathies of Upper Limb
| Code | Description | Notes / Laterality |
|---|---|---|
| G56.00 | Carpal tunnel syndrome, unspecified upper limb | Require laterality when documented |
| G56.01 | Carpal tunnel syndrome, right upper limb | Most common entrapment neuropathy; NCS confirmatory |
| G56.02 | Carpal tunnel syndrome, left upper limb | |
| G56.03 | Carpal tunnel syndrome, bilateral upper limbs | Use when bilateral carpal tunnel syndrome is documented |
| G56.10–G56.12 | Other lesions of median nerve (unsp/R/L) | Anterior interosseous syndrome, pronator syndrome |
| G56.20–G56.23 | Lesion of ulnar nerve (unsp/R/L/bilateral) | Cubital tunnel syndrome at elbow; Guyon’s canal at wrist |
| G56.30–G56.33 | Lesion of radial nerve (unsp/R/L/bilateral) | Wrist drop; spiral groove compression; Saturday night palsy |
| G56.40–G56.43 | Causalgia of upper limb (unsp/R/L/bilateral) | Complex regional pain syndrome type II (nerve injury confirmed); now classified under CRPS II |
| G56.80–G56.83 | Other specified mononeuropathies of upper limb (unsp/R/L/bilateral) | Thoracic outlet syndrome, anterior interosseous neuropathy |
| G56.90–G56.93 | Unspecified mononeuropathy of upper limb (unsp/R/L/bilateral) | Use only when the specific nerve is not documented; use specified laterality, including bilateral, when documented |
G57 — Mononeuropathies of Lower Limb
| Code | Description | Notes |
|---|---|---|
| G57.00–G57.03 | Lesion of sciatic nerve (unsp/R/L/bilateral) | True sciatic neuropathy (not radiculopathy M54.4x); EMG-confirmed |
| G57.10–G57.13 | Meralgia paresthetica (unsp/R/L/bilateral) | Lateral femoral cutaneous nerve; anterolateral thigh; no motor deficit |
| G57.20–G57.23 | Lesion of femoral nerve (unsp/R/L/bilateral) | Thigh atrophy, knee extension weakness, diminished patellar reflex |
| G57.30–G57.33 | Lesion of lateral popliteal nerve (unsp/R/L/bilateral) | Common peroneal/fibular neuropathy; foot drop; fibular head entrapment |
| G57.40–G57.43 | Lesion of medial popliteal nerve (unsp/R/L/bilateral) | Tibial nerve; plantar surface sensory loss |
| G57.50–G57.53 | Tarsal tunnel syndrome (unsp/R/L/bilateral) | Posterior tibial nerve at medial ankle; plantar pain/paresthesia |
| G57.60–G57.63 | Lesion of plantar nerve (unsp/R/L/bilateral) | Morton’s metatarsalgia included; medial/lateral plantar nerve |
| G57.70–G57.73 | Causalgia of lower limb (unsp/R/L/bilateral) | CRPS type II lower limb; confirmed nerve injury required |
| G57.80–G57.83 | Other specified mononeuropathies of lower limb (unsp/R/L/bilateral) | Obturator nerve, sural nerve, saphenous nerve entrapment |
| G57.90–G57.93 | Unspecified mononeuropathy of lower limb (unsp/R/L/bilateral) | Use only when the specific nerve is not documented; use specified laterality, including bilateral, when documented |
G58 / G59 — Other Mononeuropathies
| Code | Description | Notes |
|---|---|---|
| G58.0 | Intercostal neuropathy | Post-thoracotomy pain; rib fracture neuropathy |
| G58.7 | Mononeuritis multiplex | Multiple non-contiguous nerve involvement; query vasculitis etiology |
| G58.8 | Other specified mononeuropathies | Cutaneous nerves, digital nerves |
| G58.9 | Mononeuropathy, unspecified | Avoid when more specific code possible |
| G59 | Mononeuropathy in diseases classified elsewhere | Manifestation code; code underlying disease first (diabetes: use E-code combination instead) |
G60 — Hereditary and Idiopathic Neuropathy
| Code | Description | Notes |
|---|---|---|
| G60.0 | Hereditary motor and sensory neuropathy (HMSN) | Charcot-Marie-Tooth (CMT) disease, all types; Dejerine-Sottas; specify gene mutation in documentation when tested |
| G60.1 | Refsum’s disease | Phytanic acid storage disease; hereditary motor/sensory neuropathy type IV |
| G60.2 | Neuropathy in association with hereditary ataxia | Friedreich ataxia neuropathy component |
| G60.3 | Idiopathic progressive neuropathy | Use for cryptogenic/idiopathic SFN when no specific etiology found after workup |
| G60.8 | Other hereditary and idiopathic neuropathies | Giant axonal neuropathy, familial amyloid polyneuropathy (also E85.x) |
| G60.9 | Hereditary and idiopathic neuropathy, unspecified | Use only after full workup; no V28 payment HCC |
G61 — Inflammatory Polyneuropathies
| Code | Description | Notes |
|---|---|---|
| G61.0 | Guillain-Barré syndrome | Acute AIDP; document precipitating infection; often inpatient ICU stay; plasmapheresis or IVIG treatment |
| G61.1 | Serum neuropathy | Post-vaccination or antiserum-related neuropathy |
| G61.81 | Chronic inflammatory demyelinating polyneuropathy (CIDP) | Relapsing/progressive; IVIG maintenance therapy; AAN guidelines; HCC 193 |
| G61.82 | Multifocal motor neuropathy (MMN) | Anti-GM1 antibodies; asymmetric weakness; IVIG responsive; distinguished from ALS |
| G61.89 | Other inflammatory polyneuropathies | POEMS syndrome neuropathy component, anti-MAG neuropathy |
| G61.9 | Inflammatory polyneuropathy, unspecified | Use only when specific type not documented |
G62 — Other and Unspecified Polyneuropathies
| Code | Description | Notes |
|---|---|---|
| G62.0 | Drug-induced polyneuropathy | Code first T36–T65 adverse effect code; CIPN from chemotherapy agents; also metronidazole, isoniazid, nitrofurantoin, colchicine |
| G62.1 | Alcoholic polyneuropathy | Code also alcohol use/dependence F10.x; document quantity and duration of use |
| G62.2 | Polyneuropathy due to other toxic agents | Code first toxic substance T51–T65; lead, arsenic, organophosphate neuropathy |
| G62.81 | Critical illness polyneuropathy | Code also critical illness; ICU-acquired weakness; axonal on NCS; weaning failure |
| G62.82 | Radiation-induced polyneuropathy | Code also external cause (Y84.2); brachial plexus most common radiation site |
| G62.89 | Other specified polyneuropathies | Uremic neuropathy (code also renal failure N18.x), hypothyroid neuropathy, idiopathic SFN not meeting G60.3 criteria |
| G62.9 | Polyneuropathy, unspecified | Peripheral neuropathy NOS; last-resort code; query for etiology when used as PDx |
G63, G64 — Polyneuropathy / Neuromuscular Disorders in Other Diseases
| Code | Description | Notes |
|---|---|---|
| G63 | Polyneuropathy in diseases classified elsewhere | Manifestation code; sequence underlying disease first: amyloidosis E85.x, hypothyroidism E03.x, SLE M32.x, rheumatoid arthritis M05.x, sarcoidosis D86.x, paraneoplastic (neoplasm first) |
| G64 | Other disorders of peripheral nervous system | “Use code” — code the specific peripheral nervous system disorder; rarely assigned independently |
Diabetic Neuropathy — E-Code Combination Codes
| Code | Description | Notes |
|---|---|---|
| E11.40 | Type 2 DM with diabetic neuropathy, unspecified | Avoid when specific subtype documented; HCC 37 (high RAF) |
| E11.41 | Type 2 DM with diabetic mononeuropathy | Single nerve; code also specific nerve if documented (e.g., G56.0x for CTS in DM) |
| E11.42 | Type 2 DM with diabetic polyneuropathy | Most common; DSPN; stocking-glove distribution; HCC 37 |
| E11.43 | Type 2 DM with diabetic autonomic (poly)neuropathy | Document specific autonomic manifestation (gastroparesis, orthostatic hypotension, neurogenic bladder); code also K31.84 (gastroparesis) if documented |
| E11.44 | Type 2 DM with diabetic amyotrophy | Proximal asymmetric motor neuropathy (Bruns-Garland syndrome); thigh pain and wasting; EMG-confirmed |
| E11.49 | Type 2 DM with other diabetic neurological complication | Includes hypoglycemic neuropathy, diabetic cranial neuropathy; use when specific subtype not otherwise classified |
| E10.40–E10.49 | Type 1 DM with neuropathy (parallel structure) | Same subcategories; “with” convention applies identically |
| E08.40–E08.49 | Diabetes mellitus due to underlying condition, with neuropathy | Pancreatogenic diabetes, Cushing’s disease causing diabetes |
| E09.40–E09.49 | Drug- or chemical-induced diabetes, with neuropathy | Steroid-induced DM with neuropathy; code also T38.0x5A (corticosteroid adverse effect) |
| E13.40–E13.49 | Other specified diabetes, with neuropathy | MODY, secondary diabetes NOS; parallel subcategory structure |
Autonomic Nervous System (G90.x) and Related
| Code | Description | Notes |
|---|---|---|
| G90.01 | Carotid sinus syncope | Autonomic dysfunction at carotid sinus |
| G90.09 | Other idiopathic peripheral autonomic neuropathy | Idiopathic autonomic ganglionopathy; pure autonomic failure |
| G90.1 | Familial dysautonomia (Riley-Day syndrome) | Hereditary autonomic neuropathy type III; pediatric onset |
| G90.3 | Multi-system atrophy with orthostatic hypotension | Shy-Drager syndrome; parkinsonism + autonomic failure |
| G90.4 | Autonomic dysreflexia | Spinal cord injury setting; code also SCI (S14.x, S24.x, S34.x) |
| G90.50–G90.59 | Complex regional pain syndrome I (CRPS I), various sites | No confirmed nerve injury; reflex sympathetic dystrophy; distinguished from G56.4x/G57.7x (CRPS II with nerve injury) |
| G90.8 | Other disorders of autonomic nervous system | Postural tachycardia syndrome (POTS) coded here or R00.0 |
| G90.9 | Disorder of autonomic nervous system, unspecified | |
| B02.22 | Postherpetic trigeminal neuralgia | PHN of trigeminal distribution; G53 Excludes1 postherpetic trigeminal neuralgia; there is no G53.0 in ICD-10-CM |
| B02.23 | Postherpetic polyneuropathy | PHN with polyneuropathy pattern post-zoster |
| B02.29 | Other postherpetic nervous system involvement | PHN, other sites; Ramsay Hunt (B02.21); index directs most PHN here |
| E53.8 | Deficiency of other specified B vitamins | Vitamin B12 deficiency; code also D51.x (pernicious anemia if applicable) and G32.0 (subacute combined degeneration) |
| G32.0 | Subacute combined degeneration of spinal cord | B12 or copper deficiency; posterior + lateral column involvement; manifestation code (code B12 deficiency first) |
🔎 Indexing
Use the FY2027 ICD-10-CM Alphabetic Index primary entry for neuropathy. Key index paths:
- Neuropathy, neuropathic — main term → subterm “peripheral” → subterm by etiology (alcoholic, diabetic, drug-induced, hereditary, idiopathic, inflammatory, ischemic, toxic)
- Neuropathy, peripheral, diabetic → see E08–E13 with .40–.49
- Polyneuropathy — main term → subterms by etiology (alcoholic G62.1, critical illness G62.81, diabetic [see Diabetes, with neuropathy], drug-induced G62.0, hereditary G60.x, idiopathic G60.9, inflammatory G61.x, radiation G62.82, toxic G62.2)
- Syndrome, carpal tunnel → G56.0-
- Syndrome, tarsal tunnel → G57.5-
- Syndrome, Guillain-Barré → G61.0
- Neuropathy, CIDP → G61.81
- Disease, Charcot-Marie-Tooth → G60.0
- Meralgia paresthetica → G57.1-
- Neuralgia, post-herpetic → B02.29 (other PHN) or B02.22 (trigeminal)
- Degeneration, subacute combined → G32.0
- Dysautonomia → G90.1 (familial), G90.09 (other idiopathic)
- Syndrome, Refsum → G60.1
When the index leads to “see also Diabetes, with, neuropathy” — always confirm documentation of the specific type of diabetes (Type 1, Type 2, secondary, drug-induced) before selecting the E-code subcategory. The ICD-10-CM index for “Polyneuropathy, diabetic” does not auto-assign — it redirects to the diabetes table, where the coder must identify the specific category (E08–E13).
🏥 CPT
All CPT codes verified against the AMA CPT 2027 Professional Edition. Note: CPT codes 95900, 95903, 95904 were deleted in prior years and replaced by 95907–95913 for nerve conduction studies; use 95885–95887 for needle EMG services performed with nerve conduction studies on the same day, when documented.
CPT codes 95900 (motor NCS), 95903 (motor NCS with F-wave), and 95904 (sensory NCS) were deleted from CPT. Do not use these codes for dates of service on or after January 1, 2013. Current billing uses the “per study” family 95907–95913 for NCS; when needle EMG is performed with NCS on the same day, use 95885–95887 as applicable in conjunction with 95907–95913. Per AMA CPT guidance, a single conduction study is a sensory conduction test, motor conduction test with or without F-wave, or H-reflex test for each nerve, and each type is counted only once per nerve even when multiple sites are stimulated or recorded.
📅 Code-Set Transition — CPT 2026 (dates of service through Dec 31, 2026)
- 95924: descriptor revised for CPT 2027 to add “with interpretation and report” and clarify combined parasympathetic and sympathetic adrenergic function testing with at least 5 minutes of passive tilt (ie, tilt table).
- 11100 and 11101 were deleted before CPT 2026 and remain invalid for CPT 2026 and CPT 2027 dates of service.
🧾 HCPCS
HCPCS codes verified against the CMS HCPCS 2026 Annual Update.
| HCPCS Code | Description | Typical Use in Neuropathy |
|---|---|---|
| J1569 | Injection, immune globulin (Gammagard Liquid/Gammagard Liquid ERC), 500 mg | IVIG for CIDP (G61.81), GBS (G61.0), MMN (G61.82); Medicare LCD/payer policy varies; document diagnosis, prior authorization per payer; bill per 500 mg increment per infusion visit |
| J1561 | Injection, immune globulin (Gamunex-C/Gammaked), non-lyophilized (e.g., liquid), 500 mg | Alternative IVIG product for CIDP; same indications; verify formulary |
| J1460 | Injection, gamma globulin, intramuscular, 1 cc | IM formulation; less common for neuropathy; subcutaneous formulations preferred for CIDP maintenance |
| J7336 | Capsaicin 8% patch, per square centimeter | Focal peripheral neuropathic pain indications per FDA labeling and payer policy; physician office application; prior authorization often required; report units by square centimeters applied |
| J3420 | Injection, vitamin B12 cyanocobalamin, up to 1000 mcg | B12-deficiency neuropathy (E53.8); G32.0 subacute combined degeneration; IM or deep SC injection; typically monthly maintenance |
| J9310 | Injection, rituximab, 100 mg | Refractory CIDP, anti-MAG neuropathy, vasculitic neuropathy; off-label for most neuropathy indications; document clinical necessity |
| A4570 | Splint | Wrist splints for carpal tunnel syndrome (G56.0x); DME supplier billing; document prescription and diagnosis |
| E1399 | Durable medical equipment, miscellaneous | Specialized orthoses, ankle-foot orthosis (AFO) for foot drop (G57.30–G57.32); may require L-code (L1900 series) for AFOs |
| L1900 | AFO, spring wire, dorsiflexion assist cuff type | Foot drop from peroneal neuropathy; custom vs prefabricated; document prescription and functional indication |
| G0166 | External counterpulsation (EECP) for chronic refractory neuropathic pain | Limited coverage; check payer LCD; rarely used for neuropathy |
📚 AHA Coding Clinic
The following represents AHA Coding Clinic guidance relevant to neuropathy coding. Coders should reference original Coding Clinic issues for complete context; summaries below reflect key principles.
| Topic | Coding Clinic Reference / Guidance |
|---|---|
| Diabetic neuropathy — “with” convention | Coding Clinic has consistently affirmed that the “with” convention (ICD-10-CM Guideline I.A.15) applies to diabetes and neuropathy. The physician need not explicitly state “due to diabetes” — documentation of both conditions in the record is sufficient unless the provider states otherwise. Applies to all E08–E13 categories. |
| Diabetic autonomic neuropathy — gastroparesis | When a patient with diabetic autonomic neuropathy (E11.43) also has documented gastroparesis, code also K31.84 (gastroparesis) as an additional code per tabular instruction “code also K31.84.” |
| Chemotherapy-induced peripheral neuropathy (CIPN) | Code G62.0 (drug-induced polyneuropathy) as the neuropathy code. Sequence the adverse effect T-code (e.g., T45.1x5A for antineoplastic agents) as directed by the “code first” note at G62.0. The neoplasm may be coded as additional diagnosis if actively treated. |
| Critical illness polyneuropathy (G62.81) | Coding Clinic affirms G62.81 is appropriate for ICU-acquired polyneuropathy in the setting of critical illness/SIRS/sepsis. Code also the precipitating critical illness. This diagnosis supports ICU-level resource utilization documentation. |
| Carpal tunnel + diabetes — “with” convention | Diabetic mononeuropathy (E11.41) applies when carpal tunnel syndrome is documented in a diabetic patient — however, carpal tunnel syndrome has other common causes (occupational, idiopathic). The “with” convention is presumptive but provider documentation of the relationship is the gold standard. CDI query recommended when ambiguous. |
| GBS coding and sequencing | G61.0 is the principal diagnosis for GBS admissions. Code also any documented precipitating infection (Campylobacter jejuni enteritis A04.5, cytomegalovirus B25.9, influenza J09/J10/J11). Mechanical ventilation is coded separately by duration: 5A1935Z for less than 24 consecutive hours, 5A1945Z for 24–96 consecutive hours, or 5A1955Z for greater than 96 consecutive hours (ICD-10-PCS). |
| Post-herpetic neuralgia | Index “Neuralgia, post-herpetic” → B02.29 (most sites) or B02.22 (trigeminal distribution). G53 (cranial nerve disorders in diseases classified elsewhere) has no subcodes in ICD-10-CM and Excludes1 postherpetic trigeminal neuralgia (B02.22), so B02.22 is assigned alone for trigeminal PHN (FY 2027 Tabular). |
| Small fiber neuropathy: code assignment | The FY 2027 Alphabetic Index has no entry for “small fiber” neuropathy; code from the provider’s documented terms. Index: Neuropathy, idiopathic, G60.9; Neuropathy, idiopathic, progressive, G60.3; Polyneuropathy, sensory (idiopathic), G60.8. When an etiology is documented, use the combination code: diabetic neuropathy E08-E13 with .40 (e.g., E11.40) or diabetic polyneuropathy E08-E13 with .42 (e.g., E11.42); Sjögren syndrome with peripheral nervous system involvement, M35.06. Query CDI for etiology workup results. |
💰 HCC / Risk Adjustment
Most neuropathy codes do not map to a V28 payment HCC. Mappings below follow the 2024 CMS-HCC model (commonly called V28), which CMS uses at 100 percent for non-PACE Medicare Advantage risk scores and continued for CY 2027, and the CMS 2027 Initial ICD-10-CM Mappings. Coefficients vary by enrollee segment and payer, so this guide does not quote RAF weights; check the current CMS model software. Hierarchies are applied by CMS after coding: code every documented, supported condition.
| ICD-10-CM Code(s) | Description | V28 HCC | Coding / Documentation Notes |
|---|---|---|---|
| E10.40–E10.42, E11.40–E11.42 | Diabetes with neuropathy, mononeuropathy, or polyneuropathy | HCC 37 — Diabetes with Chronic Complications | Diabetes HCCs 36–38 share one coefficient |
| G61.81, G61.82 | CIDP; multifocal motor neuropathy | HCC 193 — Demyelinating Polyneuritis and Multifocal Motor Neuropathy | — |
| G61.0 | Guillain-Barré syndrome | No V28 payment HCC | — |
| G60.-, G62.-, G63, G61.89, G61.9 | Hereditary and idiopathic neuropathy; drug-induced, alcoholic, critical illness, and other polyneuropathy | No V28 payment HCC | Code the cause (for example, alcohol dependence F10.20, HCC 139; chemotherapy adverse effect) |
| G12.21 | Amyotrophic lateral sclerosis | HCC 190 — ALS and Other Motor Neuron Disease | — |
| G90.3 | Multi-system degeneration of the autonomic nervous system | HCC 199 — Parkinson and Other Degenerative Disease of Basal Ganglia | — |
V24 HCC 75 (myasthenia gravis, Guillain-Barré, and inflammatory and toxic neuropathy) no longer applies.
Sources: CMS 2027 Initial ICD-10-CM Mappings (2024 CMS-HCC model, V28); CMS CY 2024 Rate Announcement, Attachment VI (hierarchies, interactions); FY 2027 ICD-10-CM Tabular List, Index, and Official Guidelines. Verified November 3, 2026.
✍️ CDI Query Templates
All queries follow AHIMA/ACDIS 2019 Query Practice Brief standards: non-leading, multiple-choice format, clinical indicators stated, timeframe specified.
| Query Scenario | Sample Query Wording |
|---|---|
| Diabetic neuropathy — etiology linkage | “The patient has documented Type 2 diabetes mellitus and peripheral neuropathy with numbness and tingling in bilateral feet (NCS showing reduced amplitudes, HbA1c 9.1%). Please clarify the relationship between these conditions. Is this: (A) Diabetic polyneuropathy (neuropathy due to diabetes mellitus); (B) Peripheral neuropathy of a different etiology (please specify); (C) Unable to determine. Please document your response in the medical record.” |
| Neuropathy type — mono vs. poly | “The clinical record documents peripheral neuropathy. Electrodiagnostic studies were performed this encounter. To ensure accurate diagnosis coding, please clarify: Is this: (A) Mononeuropathy (single nerve — please specify nerve and side); (B) Polyneuropathy (multiple nerves, diffuse); (C) Mononeuropathy multiplex (multiple non-contiguous nerves); (D) Unable to specify at this time.” |
| Small fiber neuropathy — skin biopsy result | “Skin punch biopsy results document reduced intraepidermal nerve fiber density (IENFD) consistent with small fiber neuropathy. Workup for etiology was performed. Please clarify the diagnosis: (A) Small fiber neuropathy, idiopathic/cryptogenic; (B) Small fiber neuropathy due to diabetes mellitus; (C) Small fiber neuropathy due to autoimmune condition (please specify); (D) Small fiber neuropathy due to other cause (please specify); (E) Diagnosis not established at this time.” |
| Autonomic neuropathy — diabetic vs. non-diabetic | “The patient with Type 2 DM has documented orthostatic hypotension (BP drop of 24/12 mmHg on standing), gastroparesis, and reduced heart rate variability on cardiovascular autonomic testing. Please clarify: Is this: (A) Diabetic autonomic neuropathy (autonomic neuropathy due to diabetes); (B) Autonomic dysfunction due to another etiology (please specify); (C) Clinical findings are present but causation cannot be established.” |
| CIPN — agent and timing | “The patient is receiving/has received chemotherapy. Peripheral neuropathy symptoms (sensory: tingling, numbness in hands/feet) are documented. Please clarify: (A) Chemotherapy-induced peripheral neuropathy due to [specify agent, e.g., paclitaxel/oxaliplatin/vincristine]; (B) Neuropathy unrelated to chemotherapy — due to other cause (specify); (C) Neuropathy present — etiology not determined at this time.” |
| GBS — precipitating infection | “The patient has confirmed Guillain-Barré syndrome (G61.0). Recent history includes: [specify: gastroenteritis, respiratory illness, recent vaccination]. Please clarify whether there is a documented precipitating infection or trigger: (A) GBS following Campylobacter jejuni enteritis; (B) GBS following viral respiratory illness (specify if known); (C) GBS following vaccination (specify vaccine); (D) GBS — precipitating cause not established.” |
| CIDP — documentation for IVIG medical necessity | “The patient is receiving/will receive IVIG therapy for neuropathy. To support medical necessity documentation per payer requirements, please confirm the diagnosis: (A) Chronic inflammatory demyelinating polyneuropathy (CIDP); (B) Multifocal motor neuropathy (MMN); (C) Guillain-Barré syndrome (acute phase); (D) Other inflammatory neuropathy (specify); (E) IVIG for other indication (specify).” |
IVIG medical necessity and diagnosis specificity are high audit targets. Medicare requires a confirmed diagnosis of GBS, CIDP, or MMN for IVIG coverage under LCD L35050/L33547. Coding G61.81 (CIDP) without supporting documentation (nerve conduction studies showing demyelination, clinical response to IVIG, neurology evaluation) is a frequent RAC/OIG audit finding. Ensure the medical record includes: neurologist diagnosis statement, NCS/EMG reports, treatment plan, and response documentation before coding G61.81 for inpatient or outpatient IVIG claims.
🧑⚕️ Treatments (Clinical)
Treatment documentation supports medical necessity, resource utilization coding, and HCC accuracy. CDI specialists should ensure all active treatments are reflected in the diagnosis documentation.
Entrapment / Compressive Mononeuropathies
- Conservative: wrist splinting (CTS), activity modification, NSAIDs, corticosteroid injection (CPT 20526 CTS injection)
- Surgical decompression: carpal tunnel release (CPT 64721), cubital tunnel decompression/transposition (CPT 64718), tarsal tunnel release (CPT 28035), peroneal nerve decompression
- Post-surgical documentation: note surgical findings, nerve condition, expected recovery timeline
Diabetic Neuropathy
- Glycemic optimization (primary modifier for progression); document HbA1c target and achieved level
- Symptomatic pain management: pregabalin, gabapentin, duloxetine (FDA-approved for DPN), TCAs
- Foot care: preventive podiatry, custom diabetic footwear (HCPCS A5500–A5513), monofilament testing
- Cardiovascular autonomic: fludrocortisone, midodrine for orthostatic hypotension; document standing BP measurements
CIDP / Immune-Mediated Neuropathies
- IVIG: first-line; Gammagard Liquid (J1569), Gamunex-C (J1561); document loading vs maintenance dose, response assessment
- Subcutaneous immunoglobulin (SCIG): home maintenance alternative; Hizentra (J1559), Gamunex-C/Gammaked (J1561 with subcutaneous modifier when payer-required)
- Plasma exchange: second-line acute; document number of exchanges, volume treated
- Oral corticosteroids or pulse IV methylprednisolone: document dose, duration, taper
- Rituximab (J9310): refractory cases; document CD20+ B-cell depletion strategy
- Physical and occupational therapy: document functional deficits, goals, frequency
GBS (Acute Phase)
- IVIG 2 g/kg over 5 days OR plasma exchange 5 exchanges over 10–14 days (equivalent efficacy per Dutch GBS Study Group)
- ICU monitoring: respiratory function (FVC, NIF), autonomic monitoring, DVT prophylaxis
- Mechanical ventilation when FVC <15–20 mL/kg: code ICD-10-PCS ventilation by duration — 5A1935Z for less than 24 consecutive hours, 5A1945Z for 24–96 consecutive hours, or 5A1955Z for greater than 96 consecutive hours; ventilation greater than 96 hours drives the highest MS-DRG weight tier
- Pain management: gabapentin, opioids for neuropathic pain during acute phase
- Rehab: early PT/OT; long-term recovery may require inpatient rehabilitation (IRF) coding
Hereditary Neuropathy (CMT)
- No disease-modifying therapy currently available; symptom management and orthotic support
- AFO for foot drop (L-code orthoses), custom footwear, surgery for foot deformity (pes cavus correction)
- Genetic counseling: document gene mutation identified (PMP22 duplication CMT1A, GJB1 CMTX, MFN2 CMT2A)
- Avoid neurotoxic drugs (vincristine, colchicine) — document CMT diagnosis prominently in medication reconciliation
🎓 Patient Education / Summary
Patient education documentation supports coding specificity and demonstrates active management of neuropathy complications. When education is documented in the medical record, coders can confirm the diagnosis was recognized and addressed during the encounter.
Key Patient Education Points
- Foot care for diabetic neuropathy: Daily foot inspection, proper footwear, avoidance of barefoot walking, prompt reporting of wounds or skin breakdown. Lack of pain sensation means injuries may go unnoticed — patient and caregiver education is critical to preventing diabetic foot ulcers (E11.621 or E11.622; CMS-HCC V28 HCC 37).
- Medication adherence: Explain the role of gabapentinoids and duloxetine in neuropathic pain modulation (not traditional pain relievers); address side effects (drowsiness, weight gain) that affect adherence.
- IVIG home vs. infusion center: For CIDP/MMN patients transitioning to SCIG, educate on self-injection technique, site rotation, recognizing adverse reactions, and storage requirements.
- Avoidance of neurotoxic exposures: Alcohol (G62.1 — document counseling); neurotoxic medications (document medication reconciliation); occupational exposures (repetitive wrist use for CTS, tight compression garments).
- Activity and rehabilitation: Balance training, fall prevention (loss of proprioception increases fall risk — Z91.81 fall risk); assistive devices (cane, walker, AFO); swimming and low-impact exercise for CMT/polyneuropathy.
- When to call the physician: GBS warning signs — rapid spread of weakness, breathing difficulty, swallowing problems require immediate emergency evaluation; educate post-GBS patients on relapse vs. CIDP development (~3–5% of GBS develop CIDP).
- Genetic counseling (hereditary neuropathy): CMT is autosomal dominant (CMT1A/1B) or X-linked (CMTX) in most cases; family members at 50% risk for AD forms; refer to genetic counselor and Charcot-Marie-Tooth Association for resources.
Lay Summary for Documentation
Neuropathy is damage or disease affecting the nerves outside the brain and spinal cord. Depending on which nerves are affected, it can cause numbness, tingling, burning pain, weakness, or problems with automatic body functions like blood pressure, digestion, or bladder control. The most common cause is diabetes, but neuropathy can also result from immune system attacks, inherited conditions, vitamin deficiencies, certain medications, alcohol, and many other conditions. Treatment focuses on addressing the underlying cause, controlling symptoms, and preventing complications — particularly foot injuries in patients with diabetes who cannot feel pain normally.
Documentation completeness — including etiology, nerve distribution, fiber type, and response to treatment — is essential for accurate ICD-10-CM coding, appropriate HCC risk capture, and demonstration of quality care to payers and accreditors.
About this Guide
This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2027 ICD-10-CM (effective October 1, 2026) and CPT 2027 (effective January 1, 2027). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, CPT code set, HCPCS quarterly updates, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.
Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)
Ready to turn this knowledge into a credential?
These Clinical Documentation Guides are a free companion to CCO’s paid training programs. Browse our full CCO Course, Blitz & Practice Exam Catalog — every core course, review blitz, practice exam, textbook, and free resource in one place — and find the perfect next step for your coding career.
CCO Hero
Know someone starting a medical coding career?
Share your personal CCO link. Your friend saves 20% on their first course or practice exam of $100 or more, and you earn 5% cash on their first enrollment over $100.
Become a CCO Hero